Abstract
Since the introduction of the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology, much experience has been gained and published concerning the utility of the diagnostic categories, malignancy risk of the categories and reproducibility of the system. This new information has resulted in modifications to the system which will become part of the World Health Organization (WHO) System for Reporting Pancreatic Cytology. Herein we report our experience with the system and information from the published literature.
Highlights
The Papanicolaou Society of Cytopathology established a system composed of six categories, one of which is sub-divided into two sub-categories [1,2]
Even when acellular material is aspirated from a neoplastic mucinous cyst, the sample can be appropriately assigned to the “neoplasm, other” category based on gross appearance of thick mucin coupled with a carcinoembryonic Antigen (CEA) level of at least 192 ng/mL or the presence of KRAS/GNAS mutations [7,8,9,10]
Subsequent to the publication of the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology, modifications have been incorporated in the proposed World Health Organization recommendations for categorization of pancreatic neoplasms
Summary
In 2015, the Papanicolaou Society of Cytopathology (PSC) published its system for reporting pancreaticobiliary cytology [1,2]. This system was widely adopted and a number of publications reviewed experience with implementing the system, working with the system, risk stratification using the published categories and, reproducibility among observers for various categories within this system. Reviews of the Papanicolaou proposal for standardized terminology and nomenclature, have shown utility for this system [3,4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
